Key result
PROLI/NO inhibits post-injury neointimal hyperplasia more in diabetic and metabolic syndrome rodents than controls.
Why the study?
Does nitric oxide therapy prevent neointimal hyperplasia more effectively in animal models of type II diabetes and metabolic syndrome compared to controls?
Population
Rodent models of type II DM, metabolic syndrome, and their genetic control, including harvested aortic…
Comparison
Nitric oxide (NO) donor PROLI/NO vs Genetic controls and comparison across disease…
Design
Preclinical
Authors
Loading...
Hypothesis-generating for enhanced NO efficacy against restenosis in diabetes; prospective human trials needed before clinical translation.
Does nitric oxide therapy prevent neointimal hyperplasia more effectively in animal models of type II diabetes and metabolic syndrome compared to controls?
Nitric oxide-based therapies demonstrate heightened efficacy in inhibiting neointimal hyperplasia in rodent models of type II diabetes and metabolic syndrome, suggesting potential therapeutic benefits for preventing restenosis in these high-risk populations.
Ahanchi et al. (2008) studied Type II diabetes mellitus and metabolic syndrome. Nitric oxide (NO) donor PROLI/NO vs. Genetic controls (lean Zucker) was evaluated on Neointimal hyperplasia following arterial injury. Nitric oxide therapy using PROLI/NO inhibited neointimal hyperplasia following arterial injury to a greater extent in rodent models of type II diabetes and metabolic syndrome than in controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: